FDA Accepts Biodel’s New Drug Application for Review

Related Articles:

• 
  FDA Accepts Sanofi’s NDA for New Basal Insulin, Toujeo
  The U.S. Food and Drug Administration (FDA) has accepted for review Sanofi’s New Drug Application (NDA) for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The…
• 
  FDA Grants Tentative Approval to Lilly’s New Insulin…
  The U.S. FDA has granted tentative approval for Basaglar (insulin glargine injection). With a tentative approval, the FDA has determined that Basaglar meets all of the regulatory requirements for approval, but it…
• 
  FDA Approves Toujeo, Sanofi’s New Long Acting Insulin 
  The U.S. Food and Drug Administration (FDA) approved Sanofi’s new once daily long acting insulin, Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) for treatment of adults living with type…
• 
  FDA Approves Basaglar, Lilly-Boehringer Ingelheim New Long
  The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes alliance. Basaglar is a long-acting human insulin analog which is used to improve glycemic control in adult…
• 
  FDA Approves Basaglar, Lilly-Boehringer Ingelheim New Long
  The U.S. FDA approved Basaglar (insulin glargine injection), the newest diabetes treatment from the Lilly-Boehringer Ingelheim diabetes alliance. Basaglar is a long-acting human insulin analog which is used to improve glycemic control in adult…